Synapse - Thoracic Oncology

Results (3394)

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

Journal Article

Suehara, Y.; Arcila, M.; Wang, L.; Hasanovic, A.; Ang, D.; Ito, T.; Kimura, Y.; Drilon, A.; Guha, U.; Rusch, V.; more...
Clinical Cancer Research (2012)

Fulltext@MSK | Save

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer

Journal Article

Fury, M. G.; Sherman, E.; Lisa, D.; Agarwal, N.; Algazy, K.; Brockstein, B.; Langer, C.; Lim, D. ; Mehra, R.; Rajan, S. K.; more...
Journal of the National Comprehensive Cancer Network (2012)

Fulltext@MSK | Save

Non-small cell lung cancer: Clinical practice guidelines in oncology

Journal Article

Ettinger, D. S.; Akerley, W.; Borghaei, H.; Chang, A. C.; Cheney, R. T.; Chirieac, L. R.; D'Amico, T. A.; Demmy, T. L.; Ganti, A. K. P.; Govindan, R.; more...
Journal of the National Comprehensive Cancer Network (2012)

Fulltext@MSK | Save

Distinct clinical course of EGFR-mutant resected lung cancers: Results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib

Journal Article

D'Angelo, S. P.; Janjigian, Y. Y.; Ahye, N.; Riely, G. J.; Chaft, J. E.; Sima, C. S.; Shen, R.; Zheng, J.; Dycoco, J.; Kris, M. G.; more...
Journal of Thoracic Oncology (2012)

Fulltext@MSK | Save

A large retrospective analysis of pemetrexed (PEM) activity in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ) treatment

Meeting Abstract

Scagliotti, G.; Kim, D. W.; Shaw, A. T.; Ou, S. I.; Riely, G. J.; Gettinger, S.; Besse, B.; Wilner, K.; Tang, Y.; Bartlett, C. H.
Annals of Oncology (2012)

Fulltext@MSK | Save

Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or HER2-mutant or -amplified lung cancers

Meeting Abstract

Kris, M.; Goldberg, Z.; Jänne, P. A.; Kim, D.; Martins, R.; Mok, T. S. K.; O'Connell, J.; Ou, S.; Taylor, I.; Zhang, H.
Annals of Oncology (2012)

Fulltext@MSK | Save

Who should receive EGFR tyrosine-kinase inhibitors?

Journal Article

Yu, H. A.; Riely, G. J.
Lancet Oncology (2012)

Fulltext@MSK | Save

HER2 amplification: A potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation

Journal Article

Takezawa, K.; Pirazzoli, V.; Arcila, M. E.; Nebhan, C. A.; Song, X.; de Stanchina, E.; Ohashi, K.; Janjigian, Y. Y.; Spitzler, P. J.; Melnick, M. A.; more...
Cancer Discovery (2012)

Fulltext@MSK | Save

Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component

Journal Article

Paik, P. K.; Varghese, A. M.; Sima, C. S.; Moreira, A. L.; Ladanyi, M.; Kris, M. G.; Rekhtman, N.
Molecular Cancer Therapeutics (2012)

Fulltext@MSK | Save

Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas

Journal Article

Paik, P. K.; Johnson, M. L.; D'Angelo, S. P.; Sima, C. S.; Ang, D.; Dogan, S.; Miller, V. A.; Ladanyi, M.; Kris, M. G.; Riely, G. J.
Cancer (2012)

Fulltext@MSK | Save